Comparing Evolent Health (EVH) and Its Competitors
Evolent Health (NYSE: EVH) is one of 18 public companies in the “Medical Software & Technology Services” industry, but how does it compare to its peers? We will compare Evolent Health to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.
Risk and Volatility
Evolent Health has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Evolent Health’s peers have a beta of 1.33, meaning that their average share price is 33% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Evolent Health and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Evolent Health Competitors||113||479||787||16||2.51|
Evolent Health presently has a consensus price target of $30.33, indicating a potential upside of 75.85%. As a group, “Medical Software & Technology Services” companies have a potential upside of 16.36%. Given Evolent Health’s stronger consensus rating and higher possible upside, analysts clearly believe Evolent Health is more favorable than its peers.
Earnings & Valuation
This table compares Evolent Health and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Evolent Health||$361.53 million||-$51.15 million||-14.26|
|Evolent Health Competitors||$376.15 million||$34.64 million||9.08|
Evolent Health’s peers have higher revenue and earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Evolent Health and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Evolent Health Competitors||-18.37%||-12.09%||-2.31%|
Institutional and Insider Ownership
82.5% of Evolent Health shares are owned by institutional investors. Comparatively, 63.2% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 8.8% of Evolent Health shares are owned by insiders. Comparatively, 24.4% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Evolent Health beats its peers on 7 of the 12 factors compared.
About Evolent Health
Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company’s services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company’s technology platform that aggregates and analyzes data, manages care workflows and engages patients.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.